Background ACE-inhibition and lipid lowering have shown to reduce the level of albuminuria in selected patient populations with hypertension or hypercholesterolemia. PRE-VEND-IT investigated the effect of fosinopril and pravastatin on albuminuria in nonhypertensive, non-hypercholesterolemic subjects. Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864). Subjects were randomized to pravastatin 40 mg or matching placebo and to fosinopril 20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-300mg/24h), no hypertension (<160/100mmHg) and no hypercholesterolemia (<308 mg/ dl). Microalbuminuria was measured in 2x24 hour urine collection. Results Mean age was 52.1 ± 11.2 years, 67.5% was male, mean cholesterol was 223 mg/dl, mean systolic and diastolic blood pressure was 131/77 mmHg. The figure below shows the percentage change of albuminuria after three months and four years of followup. Group A (placebo) and group B (pravastatin 40mg) did not show any effect on the level of albuminuria. In contrast, group C (fosinopril 20mg) and group D (fosinopril and pravastatin) significantly reduced the level of albuminuria (p<0.001). Conclusion In contrast to pravastatin, fosinopril reduces the level of albuminuria significantly in subjects without hypertension or hypercholesterolemia.
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Effect Objective To investigate whether the effect of fosinopril on cardiovascular events differs between subjects with a high or low intima-media-thickness (IMT) in a microalbuminuric population without hypertension.
Methods Prevention of REnal and Vascular ENdstage Disease Intervention
Trial is a double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864). Subjects were randomized to fosinopril 20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-300mg/24h) and no hypertension (<160/ 100mmHg). The IMT was measured at the posterior wall of the left common carotid artery using radio frequency signal analysis obtained by M-mode ultra-sonography. IMT was dichotomized (low: IMT <1.0mm, high: IMT >1.0mm).
Results Mean age 51.3 ± 11.8 years, 65% male, mean cholesterol 223 mg/dl, mean systolic and diastolic blood pressure 130/76 mmHg. During a mean follow-up of 46.2 ± 7.0 months, 42 (4.9%) cardiovascular events occurred. The figure below shows the Cox regression analysis divided by IMT and treatment. In the subjects with low IMT (group A), fosinopril reduced the events from 5.3 % to 2.4 %, which is a relative risk reduction of 55%. In the subjects with high IMT (group B), fosinopril reduced the events from 16.3% to 7.8%, a relative risk reduction of 53% (p<0.05). Conclusion The relative risk reduction in cardiovascular events of fosinopril is equal in subjects with high and low IMT. However, the absolute risk reduction is much higher in subjects with a high IMT. The availability of an oral FXa inhibitor could extend these benefits to the ambulatory setting. We report the antithrombotic effects of an oral direct FXa inhibitor Razaxaban in a clinical study. Methods: Healthy male subjects (n=20, 27 years ±4.8) were randomized to a single oral dose of Razaxaban 25 or 100mg. Antithrombotic effects were assessed by changes in thrombus formation from baseline, using the Badimon perfusion chamber at low and high shear rates (mimicking venous and arterial flow respectively). Perfusion studies were done predose, and at 3 and 12 hours postdose. This design allowed each subject to serve as his own control. Results expressed as mean (±standard error) -aPTT in seconds and thrombus size in µm 2 . For 3 and 12 hours postdose, thrombus size results are followed in bold italics by % reduction in thrombus size from baseline. * Statistically significant (p<0.05).
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